Management Agreements in the Biotechnology Industry

107 Contracts & Agreements

Browse by Company

ACHIEVE LIFE SCIENCES, INC. (1 contract)
Actinium Pharmaceuticals, Inc. (1)
Alkermes plc. (1)
Allovir, Inc. (1)
Amgen Inc. (4)
AquaBounty Technologies, Inc. (1)
AZIYO BIOLOGICS, INC. (1)
bioAffinity Technologies, Inc. (1)
BIOMARIN PHARMACEUTICAL INC (1)
Bison Capital Acquisition Corp. (2)
Blue Water Vaccines Inc. (1)
Bone Biologics Corp (2)
CALADRIUS BIOSCIENCES, INC. (1)
Calyxt, Inc. (4)
Capstone Therapeutics Corp. (3)
Caribou Biosciences, Inc. (1)
Castle Creek Biosciences, Inc. (1)
Chardan Healthcare Acquisition Corp. (2)
Clovis Oncology, Inc. (1)
Constellation Alpha Capital Corp. (2)
Cullinan Oncology, LLC (1)
Diffusion Pharmaceuticals Inc. (1)
Gamida Cell Ltd. (1)
GENEREX BIOTECHNOLOGY CORP (1)
GeoVax Labs, Inc. (1)
GX Acquisition Corp. (6)
Health Sciences Acquisitions Corp (2)
HERON THERAPEUTICS, INC. (2)
Immix Biopharma, Inc. (1)
Immune Therapeutics, Inc. (1)
Immunome Inc. (1)
INFINITY PHARMACEUTICALS, INC. (1)
Intellia Therapeutics, Inc. (1)
Karuna Therapeutics, Inc. (1)
Karyopharm Therapeutics Inc. (1)
KBL MERGER CORP. IV (1)
Kura Oncology, Inc. (4)
Leisure Acquisition Corp. (16)
Medovex Corp. (1)
MERRIMACK PHARMACEUTICALS INC (1)
MiMedx Group, Inc. (1)
Novus Therapeutics, Inc. (3)
NTN BUZZTIME INC (2)
OPGEN INC (1)
Organogenesis Holdings Inc. (6)
Orgenesis Inc. (1)
Petra Acquisition Inc. (1)
PIERIS PHARMACEUTICALS, INC. (4)
PROGENITY, INC. (2)
RHYTHM PHARMACEUTICALS, INC. (1)
Social Capital Suvretta Holdings Corp. III (2)
Spero Therapeutics, Inc. (1)
uniQure N.V. (1)
Xenetic Biosciences, Inc. (1)
XOMA Corp (1)
Yulong Eco-Materials Ltd (1)
ZIOPHARM ONCOLOGY INC (1)

Recent Contracts

Restructuring Support Agreement, dated as of March 26, 2024, by and among the Company Parties and the certain funds managed by Highbridge Capital Management LLC (Gamida Cell Ltd., Filed With SEC on March 27, 2024)
Second Amended and Restated Limited Partnership Agreement for a Limited Partnership Called ProKidney LP, dated as of July 11, 2022, as amended as of November 14, 2023, by and... (Social Capital Suvretta Holdings Corp. III, Filed With SEC on March 22, 2024)
Cooperation Agreement, dated as of December 20, 2023, by and among the Company, Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P (BIOMARIN PHARMACEUTICAL INC, Filed With SEC on December 20, 2023)
Management Services Agreement, effective as of September 18, 2023, by and between Precision Pathology Laboratory Services, LLC and Village Oaks Pathology Services, P.A (bioAffinity Technologies, Inc., Filed With SEC on September 20, 2023)
Second Amendment to Revenue Interest Financing Agreement, dated as of August 1, 2023, by and among the Registrant, Karyopharm Europe GmbH, HealthCare Royalty Partners III, L.P.,... (Karyopharm Therapeutics Inc., Filed With SEC on August 2, 2023)
Agreement For Construction Management Services Between AquaBounty Farms Ohio LLC and Gilbane Building Company (AquaBounty Technologies, Inc., Filed With SEC on June 30, 2023)
Management Services Agreement, dated June 13, 2023, by and among WraSer, LLC, Xspire Pharma, LLC, and Blue Water Biotech, Inc (Blue Water Vaccines Inc., Filed With SEC on June 14, 2023)
Amendment to the Cooperation Agreement, dated March 21, 2023, by and among Achieve Life Sciences, Inc., Dialectic Capital Management, LP and the other parties set forth on the... (ACHIEVE LIFE SCIENCES, INC., Filed With SEC on March 23, 2023)
Cooperation Agreement, dated February 21, 2023, by and among Heron Therapeutics, Inc., Rubric Capital Management LP, the persons and entities listed on Schedule A thereto, Velan... (HERON THERAPEUTICS, INC., Filed With SEC on February 22, 2023)
Agreement, dated as of December 15, 2022, by and among Diffusion Pharmaceuticals Inc, LifeSci Special Opportunities Master Fund Ltd., LifeSci Special Opportunities Partners L.P.,... (Diffusion Pharmaceuticals Inc., Filed With SEC on December 16, 2022)
Advisory Services and Monitoring Agreement dated as of November 4, 2022 by and between Morgenesis LLC and Metalmark Management II LLC (Orgenesis Inc., Filed With SEC on November 7, 2022)
Revenue Interest Financing Agreement, dated June 16, 2022, by and between the Company and entities managed by HealthCare Royalty Management, LLC (RHYTHM PHARMACEUTICALS, INC., Filed With SEC on August 3, 2022)
Second Amended and Restated Limited Partnership Agreement for a Limited Partnership Called ProKidney LP, dated as of July 11, 2022, by and among Tolerantia, LLC, Control... (Social Capital Suvretta Holdings Corp. III, Filed With SEC on July 15, 2022)
Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement dated December 15, 2016 by and between the Registrant, CRISPR Therapeutics AG, The... (Intellia Therapeutics, Inc., Filed With SEC on February 24, 2022)
Agreement dated December 17, 2021 by and between Petra Acquisition, Inc. and Monashee Investment Management LLC (Petra Acquisition Inc., Filed With SEC on December 23, 2021)
Management Services Agreement by and between the Company and Alwaysraise LLC, dated March 18, 2021 (Immix Biopharma, Inc., Filed With SEC on October 6, 2021)
Revenue Interest Financing Agreement, dated September 29, 2021, by and between Spero Therapeutics, Inc. and entities managed by HealthCare Royalty Management, LLC (Spero Therapeutics, Inc., Filed With SEC on September 30, 2021)
Fourth Amendment to Second Amended and Restated Management Services Agreement, dated June 1, 2021, by and between the Company and Broadband Capital Partners LLC (Immunome Inc., Filed With SEC on August 16, 2021)
Second Amended and Restated Management Services Agreement, dated October 9, 2018, by and between Paragon Biosciences, LLC and Castle Creek Pharmaceuticals, LLC (Castle Creek Biosciences, Inc., Filed With SEC on July 16, 2021)
Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing, dated December 15, 2016, by... (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
Cooperation Agreement, dated as of April 16, 2021, by and among uniQure N.V., ForUniqure B.V., Forbion 1 Management B.V., Forbion International Management B.V., and Forbion... (uniQure N.V., Filed With SEC on May 10, 2021)
Amendment dated February 23, 2021 to the Expense Advancement Agreement, dated December 1, 2017 and amended on June 29, 2020, October 26, 2020 and November 30, 2020, by and between... (Leisure Acquisition Corp., Filed With SEC on February 25, 2021)
Management Services Agreement, effective as of October 1, 2014, by and between the Registrant and Araxes Pharma LLC (Kura Oncology, Inc., Filed With SEC on February 24, 2021)
Agreement, by and among ZIOPHARM Oncology, Inc., WaterMill Asset Management Corp. Robert W. Postma, Jamie Vieser, and Holger Weis, dated February 4, 2021 (ZIOPHARM ONCOLOGY INC, Filed With SEC on February 5, 2021)
Second Omnibus Amendment and Agreement dated January 12, 2021 by and between NTN Buzztime, Inc., eGames.com Holdings LLC and Fertilemind Management, LLC (NTN BUZZTIME INC, Filed With SEC on January 15, 2021)
Form of Contribution Agreement by and between Cullinan Oncology, LLC and Cullinan Management, Inc (Cullinan Oncology, LLC, Filed With SEC on January 4, 2021)
Cooperation Agreement, dated December 10, 2020, by and among Alkermes plc, Elliott Investment Management L.P., Elliott Associates, L.P., Elliott Advisors (UK) Limited and Elliott... (Alkermes plc., Filed With SEC on December 10, 2020)
Management Services Agreement, by and between Mattison Pathology, LLP d/b/a Avero Diagnostics, a Texas limited liability partnership, and Avero Laboratory Holdings, LLC, a... (PROGENITY, INC., Filed With SEC on December 1, 2020)
Amendment dated November 30, 2020 to the Expense Advancement Agreement, dated December 1, 2017 and amended on June 29, 2020 and October 26, 2020, by and between the Company and... (Leisure Acquisition Corp., Filed With SEC on November 30, 2020)
Omnibus Amendment and Agreement dated November 19, 2020 by and between NTN Buzztime, Inc., eGames.com Holdings LLC and Fertilemind Management, LLC (NTN BUZZTIME INC, Filed With SEC on November 23, 2020)
Fee Letter Agreement dated November 12, 2020 by and among the Company, the Avista Funds and the Management Company (Organogenesis Holdings Inc., Filed With SEC on November 18, 2020)
Amendment dated August 7, 2020 to the Administrative Services Agreement between the Company and Hydra Management, LLC (Leisure Acquisition Corp., Filed With SEC on November 9, 2020)
Amendment dated October 26, 2020 to the Expense Advancement Agreement, dated December 1, 2017 and amended on June 29, 2020, by and between the Company and Hydra Management, LLC,... (Leisure Acquisition Corp., Filed With SEC on October 29, 2020)
Letter Agreement, dated as of May 31, 2017, by and between HighCape Partners Management, L.P. and the Registrant (AZIYO BIOLOGICS, INC., Filed With SEC on September 14, 2020)
Form of Subscription Agreement to be executed by certain Management Creditors (GeoVax Labs, Inc., Filed With SEC on September 8, 2020)
Asset Rental Agreement, by and between ElevateBio Management, Inc. and the Registrant, dated as of May 1, 2019 (Allovir, Inc., Filed With SEC on July 6, 2020)
Amendment dated June 29, 2020 to the Expense Advancement Agreement, dated December 1, 2017, by and between the Company and Hydra Management, LLC, MLCP GLL Funding LLC and HG Vora... (Leisure Acquisition Corp., Filed With SEC on June 30, 2020)
Management Services Agreement, by and between Mattison Pathology, LLP d/b/a Avero Diagnostics, a Texas limited liability partnership, and Avero Laboratory Holdings, LLC, a... (PROGENITY, INC., Filed With SEC on June 18, 2020)
Amended and Restated Management Services Agreement, dated April 2, 2020, by and between OpGen, Inc. and Oliver Schacht (OPGEN INC, Filed With SEC on April 2, 2020)
Amendment to Investment Management Trust Agreement, dated December 5, 2019 (Leisure Acquisition Corp., Filed With SEC on March 10, 2020)